Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma

NCT04184050 is registered in ClinicalTrials.gov with Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.

NCT NCT04184050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04184050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 13, 2020
Completion date
December 31, 2026
Enrollment
100 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma in relapse, multiple myeloma of bone, multiple myeloma with failed remission